CLINICAL TRIALS PROFILE FOR LATISSE

All Clinical Trials for LATISSE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01229423 ↗	Safety and Efficacy of LATISSE® in the Augmentation of Eyelashes of Korean Subjects	Completed	Allergan	Phase 4	2009-11-01	This study will evaluate the safety and efficacy of LATISSE® (bimatoprost 0.03%) in the augmentation of eyelashes in Korean women.
NCT01387906 ↗	Latisse (Bimatoprost .03% Opthalmic Solution) for the Treatment of Hypotrichosis of the Eyebrows: Latisse Versus Placebo	Completed	Allergan	Phase 4	2011-03-01	The primary purpose of this study is to assess efficacy and safety of Latisse (bimatoprost .03% ophthalmic solution) applied to the lateral and medial eyebrows. The primary outcome is a increase in overall eyebrow prominence as measured by at least a 1-grade increase on the Global Eyebrow Assessment (GEyA) scale, from baseline to the end of the treatment which will be day 270 period.
NCT01387906 ↗	Latisse (Bimatoprost .03% Opthalmic Solution) for the Treatment of Hypotrichosis of the Eyebrows: Latisse Versus Placebo	Completed	Kenneth Beer	Phase 4	2011-03-01	The primary purpose of this study is to assess efficacy and safety of Latisse (bimatoprost .03% ophthalmic solution) applied to the lateral and medial eyebrows. The primary outcome is a increase in overall eyebrow prominence as measured by at least a 1-grade increase on the Global Eyebrow Assessment (GEyA) scale, from baseline to the end of the treatment which will be day 270 period.
NCT01448525 ↗	Study Assessing Patient Satisfaction With LATISSE® for Increasing Eyelash Prominence	Completed	Allergan	Phase 4	2011-10-01	The purpose of this study is to determine patient satisfaction with LATISSE® treatment for increasing eyelash prominence.
NCT01623479 ↗	An Observational Study of Patients Treated With Bimatoprost 0.03% (Latisse®) for Hypotrichosis of the Eyelashes	Completed	Allergan		2010-11-19	This is an observational study of patients treated with bimatoprost 0.03% (Latisse®) for at least 12 months for hypotrichosis of the eyelashes.
NCT01698554 ↗	Bimatoprost in the Treatment of Eyelash Hypotrichosis	Completed	Allergan	Phase 3	2012-11-01	This study will evaluate the safety and efficacy of bimatoprost solution formulation A compared with bimatoprost solution 0.03% (LATISSE®) and vehicle in the treatment of eyelash hypotrichosis (inadequate eyelashes).

Clinical Trial Conditions for LATISSE

Condition Name

Condition Name for LATISSE
Intervention	Trials
Eyelash Hypotrichosis	2
Hypotrichosis	2
Facial Rhytides	1
Glabellar Lines	1

Condition MeSH

Condition MeSH for LATISSE
Intervention	Trials
Hypotrichosis	5
Cutis Laxa	1
Facies	1
Alopecia Areata	1

Clinical Trial Locations for LATISSE

Trials by Country

Trials by Country for LATISSE
Location	Trials
United States	6
Korea, Republic of	1
Sweden	1
Russian Federation	1
United Kingdom	1

Trials by US State

Trials by US State for LATISSE
Location	Trials
California	3
Florida	2
Louisiana	1

Clinical Trial Progress for LATISSE

Clinical Trial Phase

Clinical Trial Phase for LATISSE
Clinical Trial Phase	Trials
Phase 4	4
Phase 3	1
Phase 2	1

Clinical Trial Status

Clinical Trial Status for LATISSE
Clinical Trial Phase	Trials
Completed	8

Clinical Trial Sponsors for LATISSE

Sponsor Name

Sponsor Name for LATISSE
Sponsor	Trials
Allergan	7
Kenneth Beer	1
Duke University	1

Sponsor Type

Sponsor Type for LATISSE
Sponsor	Trials
Industry	7
Other	3